Alan Abdulla (A Abdulla)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Multidrug Resistant

Patients Undergoing

Top Venues

Expert opinion on drug metabolism & toxicology

Antibiotics (Basel, Switzerland)

The Journal of antimicrobial chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Perrin Ngougni-Pokem, Dorian Vanneste, Stef Schouwenburg, Alan Abdulla, Matthias Gijsen, Evelyn Dhont, Dimitri Vanderlinden, Isabel Spriet, Pieter De Cock, Birgit Koch, Françoise Van Bambeke, Gert-Jan Wijnant
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy. Expert opinion on drug metabolism & toxicology (2024)
Sarah Dräger, Tim M J Ewoldt, Alan Abdulla, Wim J R Rietdijk, Nelianne J Verkaik, Christian Ramakers, Evelien de Jong, Michael Osthoff, Birgit C P Koch, Henrik Endeman, null null
Exploring the Impact of Model-Informed Precision Dosing on Procalcitonin Concentrations in Critically Ill Patients: A Secondary Analysis of the DOLPHIN Trial. Pharmaceutics 16 (2) (2024)
Tim Preijers, Anouk E Muller, Alan Abdulla, Brenda C M de Winter, Birgit C P Koch, Sebastiaan D T Sassen
Dose Individualisation of Antimicrobials from a Pharmacometric Standpoint: The Current Landscape. Drugs (2024)
Perrin Ngougni Pokem, Dorian Vanneste, Stef Schouwenburg, Alan Abdulla, Matthias Gijsen, Evelyn Dhont, Dimitri van der Linden, Isabel Spriet, Pieter A J G de Cock, Birgit C P Koch, Françoise Van Bambeke, Gert-Jan Wijnant
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy. Expert opinion on drug metabolism & toxicology (2024)
Sarah Dräger, Tim M J Ewoldt, Alan Abdulla, Wim J R Rietdijk, Nelianne J Verkaik, Christian Ramakers, Evelien de Jong, Michael Osthoff, Birgit C P Koch, Henrik Endeman, null null
Exploring the Impact of Model-Informed Precision Dosing on Procalcitonin Concentrations in Critically Ill Patients: A Secondary Analysis of the DOLPHIN Trial. Pharmaceutics 16 (2) (2024)
André Wieringa, Tim M J Ewoldt, Ravish N Gangapersad, Matthias Gijsen, Nestor Parolya, Chantal J A R Kats, Isabel Spriet, Henrik Endeman, Jasper J Haringman, Reinier M van Hest, Birgit C P Koch, Alan Abdulla, null null
Predicting Beta-Lactam Target Non-Attainment in ICU Patients at Treatment Initiation: Development and External Validation of Three Novel (Machine Learning) Models. Antibiotics (Basel, Switzerland) 12 (12) (2023)
André Wieringa, Tim M J Ewoldt, Ravish N Gangapersad, Matthias Gijsen, Nestor Parolya, Chantal J A R Kats, Isabel Spriet, Henrik Endeman, Jasper J Haringman, Reinier M van Hest, Birgit C P Koch, Alan Abdulla, null null
Predicting Beta-Lactam Target Non-Attainment in ICU Patients at Treatment Initiation: Development and External Validation of Three Novel (Machine Learning) Models. Antibiotics (Basel, Switzerland) 12 (12) (2023)
Tim M J Ewoldt, Soma Bahmany, Alan Abdulla, Anouk E Muller, Henrik Endeman, Birgit C P Koch
Plasma protein binding of ceftriaxone in critically ill patients: can we predict unbound fractions? The Journal of antimicrobial chemotherapy (2023)
André Wieringa, Tim M J Ewoldt, Ravish N Gangapersad, Matthias Gijsen, Nestor Parolya, Chantal J A R Kats, Isabel Spriet, Henrik Endeman, Jasper J Haringman, Reinier M van Hest, Birgit C P Koch, Alan Abdulla, null null
Predicting Beta-Lactam Target Non-Attainment in ICU Patients at Treatment Initiation: Development and External Validation of Three Novel (Machine Learning) Models. Antibiotics (Basel, Switzerland) 12 (12) (2023)
Birgit C P Koch, Qiaolin Zhao, Maartje Oosterhoff, Jakob van Oldenrijk, Alan Abdulla, Brenda C M de Winter, Koen Bos, Anouk E Muller
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review. Expert opinion on drug metabolism & toxicology 18 (9) (2022)
André Wieringa, Peter G J Ter Horst, Gertjan H J Wagenvoort, Annemieke Dijkstra, Alan Abdulla, Jasper J Haringman, Birgit C P Koch
Target attainment and pharmacokinetics of cefotaxime in critically ill patients undergoing continuous kidney replacement therapy. The Journal of antimicrobial chemotherapy 77 (12) (2022)
Tim Mj Ewoldt, Alan Abdulla, Nicole Hunfeld, Letao Li, Tim J L Smeets, Diederik Gommers, Birgit C P Koch, Henrik Endeman
The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review. Expert opinion on drug metabolism & toxicology 18 (6) (2022)
Eveline E Roelofsen, Alan Abdulla, Anouk E Muller, Henrik Endeman, Diederik Gommers, Annemieke Dijkstra, Nicole G M Hunfeld, Brenda C M de Winter, Birgit C P Koch
Dose optimization of cefotaxime as pre-emptive treatment in critically ill adult patients: A population pharmacokinetic study. British journal of clinical pharmacology (2022)
Alan Abdulla, Tim M J Ewoldt, Ilse M Purmer, Anouk E Muller, Diederik Gommers, Henrik Endeman, Birgit C P Koch
A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients. Expert opinion on drug metabolism & toxicology 17 (4) (2021)
Alan Abdulla, Annemieke Dijkstra, Nicole G M Hunfeld, Henrik Endeman, Soma Bahmany, Tim M J Ewoldt, Anouk E Muller, Teun van Gelder, Diederik Gommers, Birgit C P Koch
Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT). Critical care (London, England) 24 (1) (2020)
Alan Abdulla, T M J Ewoldt, N G M Hunfeld, A E Muller, W J R Rietdijk, S Polinder, T van Gelder, H Endeman, B C P Koch
The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial. BMC infectious diseases 20 (1) (2020)